While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.
In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...
As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...
A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...
In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
That is the conclusion of a report by the global Commission on Clinical Obesity – published in The Lancet Diabetes and ...
At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...
Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...